HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

NCT03553602 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped The study was stopped for feasibility

Conditions

Prostate Cancer - Recurrent

Interventions

DRUG: HDR Brachytherapy + EBRT + STAD

Sponsor

Loyola University